工作经历
工作经历:1982.7 - 1998.1 兰州医学院第一附属医院药剂科药师、主管药师、副主任药师;1998.2--至今 北京大学第三医院药剂科副主任药师、主任药师。副教授、教授。 北京大学医学部药物评价中心主任。
科研工作
主持过科技部十一五重大新药创制项目?;卫生部临床重点专科项目;国家自然科学基金面上项目;211、863、985等项目。
学术兼职
中国妇幼保健学会药事管理委员会主任委员等。担任《临床药物治疗杂志》共同主编等学术兼职。??
获奖情况
三次获得中国药学会科学技术奖三等奖
论文
1. Ye Z, Rochwerg B, Wang Y, Adhikari NK, Murthy S, Lamontagne F, Fowler RA, Qiu H, Wei L, Sang L, Loeb M, Shen N, Huang M, Jiang Z, Arabi YM, Colunga-Lozano LE, Jiang L, Koh Y, Liu D, Liu F, Phua J, Shen A, Huo T, Du B, Zhai S, Guyatt GH. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2020.2. Men P, Qu S, Luo W, Li C, Zhai S. Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis. Diabetes, obesity & metabolism. 2020;22(1):107-115.
3. Li XX, Zhuo L, Zhang Y, Yang YH, Zhang H, Zhan SY, Zhai SD. The Incidence and Risk Factors for Adverse Drug Reactions Related to Tanreqing Injection: A Large Population-Based Study in China. Frontiers in pharmacology. 2019;10:1523.
4. He N, Yan Y, Zhai S. Pantoprazole in Patients in the ICU. N Engl J Med. 2019;380(10):983-984.
5. Men P, Li XT, Tang HL, Zhai SD. Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS One. 2018;13(5):e0197321.
6. Chen K, Zhang X, Ke X, Du G, Yang K, Zhai S. Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Therapeutic drug monitoring. 2018;40(6):663-674.
7. Yan YY, Yang YH, Wang WW, Pan YT, Zhan SY, Sun MY, Zhang H, Zhai SD. Post-Marketing Safety Surveillance of the Salvia Miltiorrhiza Depside Salt for Infusion: A Real World Study. PLoS One. 2017;12(1):e0170182.
8. Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, Li DK, Liu YN, Yang KH, Zhang YY, Zhai SD. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. The Journal of antimicrobial chemotherapy. 2016;71(11):3020-3025.
9. Ye ZK, Chen K, Chen YL, Zhai SD. A protocol for developing a clinical practice guideline for therapeutic drug monitoring of vancomycin. Journal of Huazhong University of Science and Technology Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban. 2016;36(3):469-472.
10.Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2012(2):Cd008605.
著作与译著
主编、主译著作: 1.《药物治疗学》(教育部教材)中央广播电视大学出版社2005年 ,2019年;2.《牛津临床药物治疗手册》人民卫生出版社2006年; 3.《药物300--常用药物精讲》人民卫生出版社2010年; 4.《肾衰药物手册》人民军医出版社2010年;《医院药学未来发展的巴塞尔共识(2015版)释义-中国思考与实践》北京大学医学出版社2018年。 发表与合作发表SCI期刊论文100余篇。